FT538: Preclinical Development of an Off-the-Shelf Adoptive NK Cell Immunotherapy with Targeted Disruption of CD38 to Prevent Anti-CD38 Antibody-Mediated Fratricide and Enhance ADCC in Multiple Myeloma When Combined with Daratumumab

被引：14

作者：

Bjordahl, Ryan ^{[1
]}

Gaidarova, Svetlana ^{[1
]}

Woan, Karrune ^{[2
]}

Cichocki, Frank ^{[2
]}

Bonello, Greg ^{[1
]}

Robinson, Megan ^{[1
]}

Ruller, Chelsea ^{[1
]}

Pribadi, Mochtar ^{[1
]}

Dinella, Jason ^{[1
]}

Fong, Lauren ^{[1
]}

Huffman, Janel ^{[1
]}

Chu, Hui-yi ^{[1
]}

Lee, Tom ^{[1
]}

Abujarour, Ramzey ^{[1
]}

Kaufman, Dan S. ^{[3
]}

Malmberg, Karl-Johan ^{[4
]}

Miller, Jeffrey S. ^{[2
]}

Valamehr, Bahram ^{[1
]}

机构：

[1] Fate Therapeut Inc, San Diego, CA USA

[2] Univ Minnesota, Dept Med, Hematol Oncol & Transplantat, Minneapolis, MN USA

[3] Univ Calif San Diego, Dept Med, Div Regenerat Med, La Jolla, CA 92093 USA

[4] Karolinska Inst, Karolinska Univ Hosp Huddinge, Dept Canc Immunol, Inst Canc Res, Stockholm, Sweden

来源：

关键词：

D O I：

10.1182/blood-2019-131138

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

133

引用

页数：4